Suchergebnisse - "Curigliano, G"

PubPharm (12)

1

Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer

enthalten in: ESMO open | 2024

von Curigliano, G. | Dent, R. | Earle, H. | +4

2

Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer

enthalten in: Breast cancer research and treatment | 2020

von Criscitiello, C. | Vingiani, A. | Maisonneuve, P. | +3

3

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer : TREnd trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Malorni, L. | Curigliano, G. | Minisini, A. | +19

4

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer : Results from Neo-ALTTO

enthalten in: European journal of cancer (Oxford, England : 1990) | 2018

von Di Cosimo, S. | Campbell, C. | Azim, H. | +18

5

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)

enthalten in: Breast (Edinburgh, Scotland) | 2017

von Cardoso, F. | Costa, A. | Senkus, E. | +42

ErratumIn: Breast. 2017 Apr;32:269-270. - PMID 28109648

6

Ribociclib plus letrozole in early breast cancer : A presurgical, window-of-opportunity study

enthalten in: Breast (Edinburgh, Scotland) | 2016

von Curigliano, G. | Gómez Pardo, P. | Meric-Bernstam, F. | +12

7

Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Curigliano, G. | Disalvatore, D. | Esposito, A. | +9

8

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer : final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2014

von Pivot, X. | Gligorov, J. | Müller, V. | +90

CommentIn: Ann Oncol. 2015 Jun;26(6):1269. - PMID 25787921

9

High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy

enthalten in: European journal of cancer (Oxford, England : 1990) | 2013

von Zurrida, S. | Bagnardi, V. | Curigliano, G. | +9

10

Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction

enthalten in: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | 2013

von Kneubil, M. | Brollo, J. | Botteri, E. | +9